Q&A: Sen. Sanders on insulin costs and his committee’s generic drug kerfuffle

WASHINGTON — Wednesday’s Senate hearing on high costs for insulin “is not the end” of Sen. Bernie Sanders’ plans for drug pricing interrogations, he told STAT in an interview. But it will be a show.

The Vermont Independent is bringing executives from drugmakers Eli Lilly, Novo Nordisk, and Sanofi, along with pharmacy benefit managers Express Scripts, OptumRx, and CVS Health, to appear before the Senate Health, Education, Labor, and Pensions Committee this week.

“Now [it’s time] for Congress to think big, not small, and to tackle the fundamental issues as to why we pay so much for prescription drugs,” he said.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In